DR. TERRENCE WILLIAM NORCHI, M.D., M.B.A.
Osteopathic Medicine at Chieftain Ln, Natick, MA

2008003, Feb 7, 2008

Apr 25, 2007

11/740284

Rutledge Ellis-Behnke - Canton MA, US
Terrence Norchi - Natick MA, US
Stephen Kelly - Manchester MA, US

A61K 38/00, A61K 31/70, A61P 19/00, A61P 43/00, A61P 9/00

514013000, 514014000, 514023000, 514044000

A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In one embodiment, the self-assembling material comprises peptides having a sequence of amino acid residues conforming to one or more of Formulas I-IV: ((Xaa°′−Xaa+)x(Xaane1_Xaa−)y)n (I); ((Xaa′_Xaa)x(Xaa°e°−Xaa+)y)n (II); ((Xaa+−Xaa″e1)x(Xaa−Xaa″)y)n (III); and ((Xaa−XaaQe7)x(Xaa+Xaa1e″)y)n (IV), where Xaan′ represents an amino acid residue having a neutral charge; Xaa+ represents an amino acid residue having a positive charge; Xaa represents an amino acid residue having a negative charge; x and y are integers having a value of 1, 2 or 4, independently; and n is an integer having a value of 1-5. In another embodiment, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

2008027, Nov 6, 2008

Mar 14, 2008

12/049190

Rutledge Ellis-Behnke - Canton MA, US
Terrence W. Norchi - Natick MA, US
Stephen Richard Kelly - Manchester MA, US

A61K 38/10, A61K 38/02, A61P 7/00

514 14, 514 2

Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.